A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy

Trial Profile

A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs JZP 110 (Primary)
  • Indications Narcolepsy
  • Focus Registrational; Therapeutic Use
  • Acronyms TONES-002
  • Sponsors Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 07 Jun 2017 According to a Jazz Pharmaceuticals media release, data from this trial were presented at the 31st Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting.
    • 06 Jun 2017 Results from this trial published in a Jazz Pharmaceuticals Media Release.
    • 19 May 2017 This trial has been completed in Finland (End date:2017-02-07) as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top